Molecular Insight Pharmaceuticals, Inc. (fka MIPIQ)

[Kurupt]

Wont happen, i hearing someone stepping in and helping with re-structure the place, if you will Savitr is committed to invest $45 million in ...the Company, to be effected through a corporate reorganization under a Chapter 11 filing commenced on December 9, 2010.

[Capital Gains]

Single digits and I'm in!

[SharpestGeorge]

Looks good for a technical bounce. Any thoughts on a bottom here?

[BIOCREATURE]

guess i was wrong about the chart. 83 cents..

[BIOCREATURE]

The below is what a Break Out Chart looks like. 1/4 of the volume? MA lines colliding, Bolinger Bands and mid line trending up. Does anyone think for a second that the Bond holders are going throw it all away and forth MIPI in to Bankruptcy Court? if that was the case why would they allow a 11th extension? The Onalta should be starting anyday now in the EU and MIPI is NOT paying for the trials, in that they are in a licensing agreement. 23million in Treasury Bills and 10million cash. The Bond holders are going to simply be given a higher interst rate. This Company will be sold in 2011, look for a 500-900% gain the next few months.

http://www.barchart.com/chart.php?sym=MIPI&style=classic&p=DO&d=L&size=L&log=0&ed=10%2F31%2F2010&v=0&o1=&o2=&o3=&ch1=013&ch1a=&ch1b=&ch1c=&ov1=029&ov1a=&ov1b=&ov1c=&ch2=073&ch2a=&ch2b=&ch2c=&ov2=066&ov2a=&ov2b=&ov2c=&submitted=1&fpage=&txtDate=&x=58&y=12

[piano benchpress]

Sold most of my position PM @ 4.27-4.30.

[piano benchpress]

As I said previously this has been a day-trader's dream stock. Yesterday it was easy to trade up 10% and I believe if one carefully watches the action (PM if there is any today) one will be able to day trade another 10-20%.

I had no liquidity problems for a fairly decent size position. Getting in at my low was done in partials, but nevertheless executed. Getting out was an immediate execution.

I wish all good luck with their trades today. Make some MONEY!

[mlkrborn]

PIANO BENCHER
New To MIPI. Up 0.14 to 1.14 today on yesterday's press release!
GL

[mlkrborn]

Molecular Insight Pharmaceuticals Data Indicate Trofex(TM) May Enable Visualization and Monitoring of Response to Prostate Cance
Date : 10/19/2010 @ 4:30PM
Source : MarketWire
Stock : Molecular Insight Pharmaceuticals, Inc. (MIPI)
Quote : 1.13 0.14 (14.14%) @ 7:22AM


Molecular Insight Pharmaceuticals Data Indicate Trofex(TM) May Enable Visualization and Monitoring of Response to Prostate Cance
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Intraday Stock Chart

Today : Wednesday 20 October 2010
Click Here for more Molecular Insight Pharmaceuticals (MM) Charts.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), this week presented data from a preclinical study that indicate Trofex™ ((123)I-MIP-1072), its lead molecular imaging candidate for the detection of metastatic prostate cancer, may also be used to visualize changes in tumor volume in response to treatment of the disease. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Molecular Markers in Cancer Conference in Hollywood, Florida, on October 18, 2010.

Trofex is a radiolabeled, small molecule that binds prostate specific membrane antigen (PSMA), a protein highly expressed by prostate cancer cells, with high affinity and specificity. The high degree of uptake and retention of Trofex in prostate cancer cells allows for non-invasive molecular imaging of prostate cancer.

In addition to the ability to rapidly visualize and monitor prostate cancer activity, there is a growing interest in improved methods to measure response to treatment of the disease. Traditional endpoints used to measure disease response in most oncology clinical trials are not adequate to evaluate metastatic prostate cancer.

Currently, paclitaxel is commonly used to treat advanced and recurrent prostate cancer. In the ASCO poster presentation, titled "Monitoring prostate cancer response to paclitaxel by molecular imaging of PSMA," Molecular Insight reported that the uptake of Trofex in animal models of human prostate cancer was shown to be proportional to tumor mass, suggesting that Trofex may visualize changes in tumor volume and therefore response to treatment or progression.

"The ability to assess tumor burden in prostate cancer is important for optimizing disease management, said John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development, and senior author. "With recent and pending approvals of therapies for hormone refractory prostate cancer, the ability to objectively track tumor response will help determine whether treatments are working and when new treatments need to be introduced. This type of measurement will also be important for more rapidly assessing the effectiveness of new therapies being developed for prostate cancer."

Study summary: It was demonstrated that paclitaxel inhibited the growth of human prostate tumor (LNCaP) cells in culture, and binding of Trofex was proportional to the density of live cells. Paclitaxel did not alter PSMA expression in these cells. Treatment of human prostate tumors in mice with paclitaxel resulted in a decrease in tumor volume (-19%) compared to an increase in tumor volume in the untreated control mice (+217%). Tumor uptake of Trofex was proportional to changes in tumor mass: decreased in paclitaxel treated tumors and increased in tumors of untreated mice.

The authors concluded that treatment of LNCaP cells or xenograft tumors with paclitaxel resulted in growth inhibition which was detected with Trofex. The high specificity of Trofex for prostate cancer may allow monitoring of changes in tumor burden in response to chemotherapy.

About Prostate Cancer

According to the American Cancer Society, more than 2.5 million men are currently affected by prostate cancer and approximately 200,000 new cases are diagnosed annually. While early diagnosis has improved overall survival rates, prostate cancer is the second leading cause of cancer death among men in the United States. Most prostate cancer mortalities occur when the disease has spread and therefore staging and monitoring the disease accurately is critically important in improving patient outcomes.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. Molecular Insight has five clinical-stage candidates in development. For further information on Molecular Insight Pharmaceuticals, please visit www.molecularinsight.com.

[mlkrborn]

MIPI
Molecular Insight Pharmaceuticals(MIPI_) shares were declining Monday after rocketing by as much as 80% Friday. The troubled company -- on the verge of being delisted by Nasdaq -- said an early-stage clinical trial of a cancer diagnostic test showed positive results vs. a rival technology.

The stock finished Monday by sinking 15.8% to $1.07. Also on Friday, Molecular Insight received another waiver extension from its bondholders as it struggles to refinance its debt load.

[piano benchpress]

Well, this has been a day-trader's dream stock over the course of the last two trading days. Today alone there was a 50% swing and sufficient volume to suppress any liquidity fears. I wanted to co-moderate this board, but apparently no one follows it and/or has the time and energy to devote to do the job. In this interim period, I will post any information I feel is pertinent and would be helpful to those who trade these shares.

I bought this strictly on the extraordinary increase in volume (last week) coupled with the fact that it was near its yearly low and had a high of over $6.00. From what little DD I've done thus far, I believe they have an interesting product that they are trying to bring to market and this could POTENTIALLY be a turn-around opportunity.

These are my opinions only. I don't advise others what to do with their money. And unlike many other boards, I will voice both negative and positive nuggets of information. If I think the stock is a good short, I will say so. If I feel one should accumulate, I will say so. But for the moment, I will say nothing until I have ample time to gather relevant DD.

If anyone has pertinent information regarding MIPI, please post it. I would greatly appreciate it. Many thanks.

GLTA!

[piano benchpress]

I see that no one has posted on this site, nor has an interest in co-moderating it. I, unfortunately, cannot devote enough time and energy to do this alone, so I will retract my offer of being a co-moderator. I wish all success in their trades with MIPI.

[piano benchpress]

I believe this could be a very interesting turn-around story and would like to get as much DD as I can on MIPI.

[piano benchpress]

Does anyone know if there has ever been a moderator on this board?

[piano benchpress]

Does anyone have any interest in co-moderating this board?

[Antisemetic Asshole30]

First of all my congratulations to everybody who bought this stock for less than me. You are genius all!
I own over 250 stocks and MIPI was proudly added there yesterday thou at the higher price than on Thursday. I am preparing a blog about MIPI (link in profile, my blog is about my positions) but from what I see already, it looks like a complete turnaround story, so rare in biotech sector these days. OK, so I bought 20,000 shares at $1.44 should I be happy about that if close was $1.33. Yes, I am very happy because yearly high was $6.50 and $0.70 low looks like a history with current news so $1.44 must be a fairly fair price. I am entering this stock with very good feeling about it, more will be posted in a blog and here, later.

[piano benchpress]

I'm surprised this board is so quiet. I alerted several people last night when the stock was at .81. I could only buy and sell several thousand shares as the volume yesterday (although triple normal) was only 165K. I rebought today at .98 and was able to make another .43 during market hours when there was no liquidity problem.

I am curious to know if any one feels this run is not over as I sold my entire position, not wanting to hold it over the weekend?

Any thoughts? And congrats to those of you who bought on my alert and those who didn't and still made some quick cash. Good weekend to all!

[jindal]

so that was good news after the bell today. Right?

[sherwood37]

here comes the before lunch run

[jindal]

so no resistance until $2.50?

[trythisagain]

MIPI .91 Chart:
BM's 9

[surf1944]

Molecular Insight Pharmaceuticals' Zemiva Phase 2 Data Published in Journal of the American College of Cardiology

http://finance.yahoo.com/news/Molecular-Insight-iw-3198515832.html?x=0&.v=1

[surf1944]

Molecular Insight Pharmaceuticals Presents Positive Data From Azedra(TM) Phase 2a Clinical Trial in Neuroblastoma Tumors

http://finance.yahoo.com/news/Molecular-Insight-iw-2609686862.html?x=0&.v=1

[invest2win]

It's looks like the pump didn't work this time. They are trying their hardest to keep this above a dollar. As long as the Bankruptcy looms in the background nobody cares. Just get the darn thing resolved already one way or another and stop stalling. Then maybe we can get somewhere.

[invest2win]

Why don't they just file for Bankruptcy now and save some time.

[invest2win]

Yeah probably a bounce under a dollar. Let's face it this one is garbage. It's only a matter of time before Bankruptcy

[pelicaninnc]

All that time spent on keeping it Nasdaq listed and now 1.39? I think you will see a huge bounce somewhere in here.

[invest2win]

Wow this stock is horrible!

[Legato]

Molecular Insight Receives Second Extension of Waiver Agreement With Bond Holders
http://biz.yahoo.com/iw/100518/0621547.html?.v=1

[Legato]

New MIPI 8K out http://biz.yahoo.com/e/100517/mipi8-k.html

[invest2win]

Tomorrow is the expiration date on the Bond holders extension. Got to be a PR in between somewhere. This could be the beginning or the end. We shall see!

[happymario]

just my opinion

I had 4k shares of mipi last december av 2.20.Then it dropped more than 20 days non stop and at some point My sares were sold with big losses around 1.30 share . So then i dtraded sideways and with a pr's it wentto 4$,congrat to those who took profit.

What I wanted to say is that after reading their 1q results it seems to me that mipi is nothing special at all ,I think that they wanted to pump up the pps with the pr of those great testing results only to stay on nasdaq ,since then a lot of shareholders are bleeding.

glta

[surf1944]

Molecular Insight Pharmaceuticals, Inc. Announces First Quarter 2010 Financial and Operational Results

Press Release Source: Molecular Insight Pharmaceuticals, Inc. On Thursday May 6, 2010, 4:01 pm
CAMBRIDGE, MA--(Marketwire - 05/06/10) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ:MIPI - News), today announced financial results for the first quarter ended March 31, 2010. Molecular Insight also announced that its 2010 Annual Meeting of Stockholders will be held at 10:00 a.m., Eastern Time, Wednesday, May 12, 2010, at the offices of Foley & Lardner LLP, 111 Huntington Avenue, Boston, MA.

Financial Highlights of the First Quarter 2010
For the first quarter 2010, the Company reported a net loss of $17.5 million, compared to a net loss of $15.3 million in the first quarter of 2009. The increase in net loss was primarily attributable to an increase in operating expenses of $2.5 million. Operating expenses were $12.9 million in the first quarter 2010 and increased by 24 percent from the first quarter 2009, due to increases in research and development expenses of $1.5 million and in general and administrative expenses of $1.0 million.


Research and Development expenses were $7.5 million, as compared to $6.0 million for the same period last year. The increase is primarily attributable to the build-out of a commercial-scale Azedra™ manufacturing suite and an increase in grant-related activities, as well as payroll costs for severance related to the workforce restructuring announced in early January of this year. These spending increases were partially offset by a decline in expenditures related to reduced activities for the Onalta™, Solazed™ and Zemiva™ programs as the Company plans the next phases of its clinical trials.

General and administrative expenses were $5.4 million for the first quarter of 2010, compared to $4.4 million in the first quarter of 2009. This increase is due primarily to legal costs incurred in connection with our ongoing discussions and negotiations with the Company's Bond holders regarding the restructuring of its debt obligations.

At March 31, 2010 the Company had approximately $47.1 million in cash, cash equivalents, and short-term investments, 25,268,327 shares of common stock outstanding and $190.4 million of Senior Secured Bonds and accrued and unpaid interest.

Molecular Insight's Waiver Agreements with Bond Holders
On March 15, 2010, Molecular Insight executed a waiver agreement with holders of the Company's outstanding Senior Secured Bonds and the Bond Indenture trustee and announced ongoing discussions with the holders of its Bonds concerning a restructuring of its outstanding debt. Under the terms of the waiver agreement, the Bond holders and Bond Indenture trustee agreed to waive a default arising from the inclusion of a going concern explanatory paragraph in the independent auditor's report on the Company's financial statements for the year ended December 31, 2009 and other technical defaults under the Bond Indenture until 12:01 a.m., Eastern Time on April 16, 2010. On April 15, 2010, the term of the waiver was extended until 12:01 a.m., Eastern Time on May 18, 2010.

"The waiver extension executed this quarter allows us to continue productive discussions with our Bond holders with the aim of reaching an agreement designed to avoid an acceleration of our debt obligation under the Bond indenture," said Daniel L. Peters, President and CEO of Molecular Insight. "We look forward to reporting the outcome of these discussions on or before May 18, 2010."

First Quarter Product Development Update
In the first quarter, Molecular Insight initiated a Phase 1 clinical trial of Solazed (Ioflubenzamide I-131), the Company's targeted radiotherapeutic drug candidate for treatment of malignant metastatic melanoma. The Phase 1 proof-of-concept study is being conducted with the University of Pennsylvania and is funded by a two-year grant from the National Cancer Institute that could total as much as $1.5 million.

The Company also recently announced that results from a completed Phase 2 clinical trial of Onalta (Yttrium-90 edotreotide) had been published in the peer-reviewed Journal of Clinical Oncology. The previously unpublished results from the Phase 2 clinical trial of 90 patients show that treatment with Onalta improved symptoms associated with metastatic carcinoid tumors. The trial, which ran from 2001 to 2004, was conducted by Novartis, from whom Molecular Insight licensed Onalta in 2007.

Conference Call
The Company expects to host its next conference call upon the completion of debt restructuring discussions with its Bond holders.

[surf1944]

MIPI hitting support lines currently, but the $1.50 open gap from the last big move will be real support for the stock....

[Legato]

I am not sure. That is just an agreement. Hopefully,(better be soon) sales could be announced. imo

[invest2win]

Does this mean another 10 cent rise?

Seriously does this mean they are trying to get money to take care of the Bond Holders?

[Legato]

SEC form 8K http://biz.yahoo.com/e/100504/mipi8-k.html

[invest2win]

OK so I was wrong 18 cents. Still nobody cares. Until we get a PR about the stupid bond holders issue being resolved and the word Bankruptcy is removed from PR's this is never going anywhere.

[invest2win]

New out! That should raise it about 10 cents for about 2 hours.

[invest2win]

News Out!

http://ih.advfn.com/p.php?pid=nmona&article=42410825&symbol=MIPI

[invest2win]

Oh well we can't win them all. I think this will make a good move again eventually. It certainly moves up fast when it does. Put it on the back burner.

[invest2win]

Pre-Pre Market opening looking good on high of 3.57. We may be moving up again!

[invest2win]

New StockPreacher alert

http://ih.advfn.com/p.php?pid=nmona&article=42390615&symbol=MIPI

[invest2win]

Yes I figured that! I found it by entering the symbol.

[EastCoastCdn]

lol, otcbb.com links used to default to MSFT, not that I would have experienced this in the past, thats just something I heard.. yes thats it... something I heard :)

[Legato]

Thank you, eastCoastCdn. Jessica Alba has not appeared on a instructional video. lol

[EastCoastCdn]

You would have to enter MIPI into the quote box, GE is the default company when you open that link..

Try this link

http://www.sec.gov/Archives/edgar/data/1340752/000119312510083134/0001193125-10-083134-index.htm

or

http://www.sec.gov/Archives/edgar/data/1340752/000119312510083134/ddef14a.htm

[invest2win]

What is this? I see the OTCBB page with the GE symbols.

[Legato]

DEF 14A Form http://www.otcbb.com/asp/Info_Center.asp


javascript:qm_showOutline('ipage=6889181', 'MIPI', 'MOLECULAR INSIGHT PHARMACEUTICALS, INC.: DEF 14A')

[invest2win]

Back to biz as usual I see for mee pee. Wouldn't want to make a two day run or anything. I'm glad I took my profits!